Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It's on Twitter... ASCO Results

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 04, 2023 8:05pm

208 Views

Post# 35479574

RE:RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO Results

The value of the Bracelet-1 results are significant with the major take-away being that the Bracelet-1 Phase 2 trial validates the results of the earlier IND-213 study in demonstrating that pelareorep is a single agent cancer killing drug that can be used alone or in combination with other I/O agents.

And this overcomes the issue of assessing combination regimens since combinations are difficult to assess without comparing with individual components. Now pelareorep can be asessed in combination with other drugs.

https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=35472660

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December